Abstract
Breast and prostate cancer frequently metastasizes to the skeleton and causes bone destruction. In skeletal tissue, transforming growth factor-β (TGF-β) is a major bone-derived factor responsible for driving a feed-forward vicious cycle of breast cancer growth in bone. TGF-β is released from bone in active form by osteoclastic resorption and increases the tumor secretion of factors, which stimulate osteolytic destruction of the bone adjacent to the tumor. Moreover it activates epithelial-mesenchymal transition and tumor cell invasion, increases angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor and bone offers a target for therapeutic intervention to decrease skeletal metastasis. Here we summarize the current knowledge of TGF-β in bone metastases, the use of TGF-β inhibitors and its potential for clinical use and consequences.
Keywords: TGF-β, TGF-β receptors, bone, metastases, TGF-β inhibitors, bone metastases, breast cancer, prostatic cancer, melanoma
Current Pharmaceutical Design
Title: TGF-β Pathway as a Therapeutic Target in Bone Metastases
Volume: 16 Issue: 11
Author(s): Patricia Juarez and Theresa A. Guise
Affiliation:
Keywords: TGF-β, TGF-β receptors, bone, metastases, TGF-β inhibitors, bone metastases, breast cancer, prostatic cancer, melanoma
Abstract: Breast and prostate cancer frequently metastasizes to the skeleton and causes bone destruction. In skeletal tissue, transforming growth factor-β (TGF-β) is a major bone-derived factor responsible for driving a feed-forward vicious cycle of breast cancer growth in bone. TGF-β is released from bone in active form by osteoclastic resorption and increases the tumor secretion of factors, which stimulate osteolytic destruction of the bone adjacent to the tumor. Moreover it activates epithelial-mesenchymal transition and tumor cell invasion, increases angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor and bone offers a target for therapeutic intervention to decrease skeletal metastasis. Here we summarize the current knowledge of TGF-β in bone metastases, the use of TGF-β inhibitors and its potential for clinical use and consequences.
Export Options
About this article
Cite this article as:
Juarez Patricia and A. Guise Theresa, TGF-β Pathway as a Therapeutic Target in Bone Metastases, Current Pharmaceutical Design 2010; 16 (11) . https://dx.doi.org/10.2174/138161210791034049
DOI https://dx.doi.org/10.2174/138161210791034049 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Repurposing in Anticancer Reagent Development
Combinatorial Chemistry & High Throughput Screening Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Current Signal Transduction Therapy Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Current Pharmaceutical Biotechnology A Number of the N-terminal RASSF Family: RASSF7
Anti-Cancer Agents in Medicinal Chemistry NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds
Current Neuropharmacology Molecular Docking Studies of Novel Thiosemicarbazone-based Indoles as Potential PI3Kα Inhibitors
Letters in Drug Design & Discovery Niosomal Gel for Site-Specific Sustained Delivery of Anti-Arthritic Drug: In Vitro-In Vivo Evaluation
Current Drug Delivery Bioinformatics Approach for Data Capturing: The Case of Breast Cancer
Current Cancer Therapy Reviews Role of microRNA Deregulation in Breast Cancer Cell Chemoresistance and Stemness
Current Medicinal Chemistry Nanoparticles in Melanoma
Current Medicinal Chemistry Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Synthesis and Evaluation of Novel Erucin Analogues as Potential Antitumor Compounds
Letters in Organic Chemistry Subject Index To Volume 2
Current Immunology Reviews (Discontinued) OIP5-AS1: A Fascinating Long Noncoding RNA in Carcinoma
Current Pharmaceutical Design Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy
Current Drug Metabolism Covalently and Ionically Crosslinked Chitosan Nanogels for Drug Delivery
Current Pharmaceutical Design